683 Capital Management LLC Buys New Holdings in Alto Neuroscience, Inc. $ANRO

683 Capital Management LLC bought a new stake in Alto Neuroscience, Inc. (NYSE:ANRO) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 64,782 shares of the company’s stock, valued at approximately $1,153,000.

Other hedge funds have also bought and sold shares of the company. ExodusPoint Capital Management LP acquired a new position in shares of Alto Neuroscience in the fourth quarter valued at $334,000. OMERS ADMINISTRATION Corp acquired a new position in shares of Alto Neuroscience in the fourth quarter valued at $221,000. Spruce Street Capital LP acquired a new position in shares of Alto Neuroscience in the fourth quarter valued at $3,967,000. Barclays PLC increased its holdings in shares of Alto Neuroscience by 72,261.9% in the fourth quarter. Barclays PLC now owns 30,392 shares of the company’s stock valued at $541,000 after purchasing an additional 30,350 shares during the last quarter. Finally, Hudson Bay Capital Management LP acquired a new position in shares of Alto Neuroscience in the fourth quarter valued at $619,000.

Analysts Set New Price Targets

Several research firms have commented on ANRO. Wall Street Zen downgraded shares of Alto Neuroscience from a “hold” rating to a “strong sell” rating in a report on Sunday, May 17th. Chardan Capital restated a “buy” rating and issued a $30.00 price target on shares of Alto Neuroscience in a research note on Wednesday, April 22nd. Robert W. Baird decreased their price target on shares of Alto Neuroscience from $38.00 to $36.00 and set an “outperform” rating on the stock in a research note on Monday, May 18th. JonesTrading decreased their price target on shares of Alto Neuroscience from $49.00 to $44.00 and set a “buy” rating on the stock in a research note on Thursday, April 2nd. Finally, Bank of America initiated coverage on shares of Alto Neuroscience in a research note on Tuesday, May 5th. They issued a “buy” rating and a $35.00 price target on the stock. Eight investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $35.25.

Alto Neuroscience Trading Up 4.2%

ANRO opened at $21.87 on Thursday. The company has a 50-day simple moving average of $22.68 and a 200 day simple moving average of $19.72. Alto Neuroscience, Inc. has a twelve month low of $2.15 and a twelve month high of $28.44. The company has a quick ratio of 20.52, a current ratio of 20.52 and a debt-to-equity ratio of 0.07. The stock has a market capitalization of $767.49 million, a price-to-earnings ratio of -9.04 and a beta of 1.22.

Alto Neuroscience (NYSE:ANRO) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($0.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.24). Analysts predict that Alto Neuroscience, Inc. will post -3.01 EPS for the current fiscal year.

Alto Neuroscience Company Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.